Investing.com - Mirum Pharmaceuticals reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Mirum Pharmaceuticals announced earnings per share of $-1.02 on revenue of $18.78M. Analysts polled by Investing.com anticipated EPS of $-1.05 on revenue of $20.32M.
Mirum Pharmaceuticals shares are down 0.45% from the beginning of the year and are trading at $20.17 , down-from-52-week-high.
Mirum Pharmaceuticals shares lost 15.75% in intra-day trade the report.
Mirum Pharmaceuticals follows other major Healthcare sector earnings this month
Mirum Pharmaceuticals's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar